4 results
The primary objective is to characterize the change in the Pharmacodynamic (PD) biomarker, fecal calprotectin, during treatment with anrukinzumab.The secondary objectives include:* Characterization of the PK profile and total IL-13 of three multiple…
To assess angiographic and clinical outcomes after treatment of ISR of a prior BMS in the native coronary system with the Lutonix Catheter
The primary objective is to assess the feasibility, safety and efficacy of Lutonix Catheter for treatment of de novo coronary artery stenosis using two distinct treatment strategies: Lutonix Catheter before or after BMS
The primary objectives are to:1) Adapt and optimize sequences and protocols to enable acquisitions during exercise with MRI and/or surface EMG.2) Perform a study in healthy volunteers using the sequences and protocols developed in 1) to correlate MR…